• Home
  • PHILOSOPHY
  • Portfolio
  • Team
  • Blog
  • Home
  • PHILOSOPHY
  • Portfolio
  • Team
  • Blog
VIEW ALL
< PREV
NEXT >
Picture
Picture
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. We are focused on providing new treatment options for cardiometabolic diseases through our complementary, convenient, cost-effective product candidate, gemcabene (CI-1027 licensed from Pfizer in 2011), as add-on to the standard of care especially statins that will benefit patients, physicians, and payors. ​
SOCIAL MEDIA: 
Website: http://www.gemphire.com/index.php
Facebook: https://www.facebook.com/pages/Gemphire-Therapeutics/1856481207940293
LinkedIn: https://www.linkedin.com/company-beta/10898628/
LOCATION:
17199 N. Laurel Park Dr., Suite 401 Livonia, MI 48152
PEOPLE:
CEO (interim): Mr. Steve Gullans 

IN THE NEWS

March 10, 2017
Picture
Gemphire Therapeutics Announces $12.5 Million Financing
May 1, 2017
Picture
Gemphire to Present at ATVB|PVD 2017 Scientific Sessions
May 31, 2017
Picture
Gemphire's Path To Success
June 1, 2017
Picture
Gemphire's Path To Success
Picture

HOME

PHILOSOPHY

PORTFOLIO

TEAM

BLOG

Copyright © 2017 Trout Creek Ventures. All Rights Reserved.​
  • Home
  • PHILOSOPHY
  • Portfolio
  • Team
  • Blog